PESHAWAR: The National Accountability Bureau has approved inquiry against Agency Surgeon of North Waziristan, FATA Secretariat and FATA Development Authority officers over corruption and misuse of powers. The Executive Board of the NAB Khyber Pakhtunkhwa met in Peshawar on Thursday with the director general in the chair. Inquiry was also approved..
Last week, La Jolla Pharmaceutical Company received FDA approval for their low blood pressure injectible Giapreza. The intravenous injectible is used to raise blood pressure in adults with certain symptoms like sepsis, shock, and hypertension, but can also cause dangerous blood clots. In a 321 patient clinical trial Giapreza raised blood pressure a
Approved by the FDA in November 2017, the new treatment option can be best described as a combination between Vivitrol and Suboxone. I'm all for giving people choices, " Hocking County Municipal Court Judge Fred Moses said. However, Indivior Inc., which produces Sublocade, has stated that it will offer a co-pay assistance program as well as a Subox
By a News Reporter-Staff News Editor at Health& Medicine Week Boston Scientific Corporation announced that it has received approval from the U.S. Food and Drug Administration for the Vercise? Deep Brain Stimulation System. The approval was based on the INTREPID study, the first multi-center, prospective, double-blind, randomized sham-controlled
By a News Reporter-Staff News Editor at Drug Week Chemence Medical, Inc., a manufacturer and distributor of adhesive-based medical devices, announced it received Food and Drug Administration clearance to market and sell Exofin Fusion , a new skin closure system for medium to large wounds. Exofin Fusion combines a self-adhering flexible mesh str
Glenmark's current portfolio consists of 130 products authorized for distribution in the U.S. marketplace and 58 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio
Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for RXDX-106, a novel oral immunomodulatory agent and TAM inhibitor, in patients with solid tumors. In preclinical studies, RXDX-106 has demonstrated the pot
Pharma major Lupin Ltd today said it has received final approval from the US health regulator for its generic version of Dovonex scalp solution used in treatment of psoriasis of scalp. The approval by the US Food and Drug Administration to Lupin`s calcipotriene topical solution is for strength of 0.005 per cent, the company said in a statement.
Lupin, through its filing on BSE, has informed that it has received final approval for its Calcipotriene Topical Solution, 0.005% from the United States Food and Drug Administration to market a generic version of Dovonex Scalp Solution, 0.005% of Leo Pharmaceutical Products Ltd.. Lupin s Calcipotriene Topical Solution, 0.005% is the AT rated gen
HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2017/ PRNewswire/ Global pharmaceutical leader Mylan N.V. today announced the U.S. launch of Estradiol Vaginal Cream USP, 0.01%, the first generic version of Allergan's Estrace Cream. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application
LAVAL, Quebec- Bausch+ Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., today announced that the U.S. Food and Drug Administration has approved LUMIFY as the first and only over-the-counter eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness.
'Shock, the inability to maintain blood flow to vital tissues, can result in organ failure and death,' said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA's Center for Drug Evaluation and Research.' There is a need for treatment options for critically ill hypotensive patients who do not ade
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative...
Roche today announced the US Food and Drug Administration has approved Perjeta, in combination with Herceptin and chemotherapy, for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.1 People should receive the adjuvant Perjeta-based regimen for one year. The FDA has also converted the previously granted accelerated.
Today, the U.S. Food and Drug Administration cleared a new noninvasive stereotactic radiotherapy system intended for use in treating cancer in breast tissue. 'With today's clearance, patients will have access to a treatment option that provides greater accuracy in delivering radiation therapy to breast tumors while saving surrounding breast tissue,
South San Francisco, CA- Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration has approved Perjeta, in combination with Herceptin and chemotherapy, for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence. The FDA has also converted the previously granted accelerated approval of
Horizon Pharma plc today announced the U.S. Food and Drug Administration has approved an expansion to the indication for PROCYSBI delayed-release capsules to include children one year of age and older living with nephropathic cystinosis. PROCYSBI was previously FDA- approved for adults and children as young as two years of age. Data included in the
The House of Representatives has approved on third and final reading a measure that seeks to regulate the importation, manufacture, distribution, and sale of children's products containing hazardous chemicals. Under the bill, the Food and Drug Administration shall prepare a list of hazardous chemicals which are to be banned or prohibited from being
SAN DIEGO- La Jolla Pharmaceutical Company today announced that the U.S. Food and Drug Administration has approved GiaprezaTM to increase blood pressure in adults with septic or other distributive shock. 'We appreciate FDA's rapid review and approval of Giapreza and are especially grateful to the patients, families and dedicated critical care teams
Lupin, through its filing on BSE, has informed that it has received final approval for its Calcipotriene Topical Solution, 0.005% from the United States Food and Drug Administration to market a generic version of Dovonex Scalp Solution, 0.005% of Leo Pharmaceutical Products Ltd.. The Company is a significant player in the Cardiovascular, Diabetolog
KENILWORTH, N.J.& NEW YORK- Merck, known as MSD outside the United States and Canada, and Pfizer Inc., today announced that the U.S. Food and Drug Administration has approved STEGLATROTM tablets, an oral sodium-glucose cotransporter 2 inhibitor, and the fixed-dose combination STEGLUJAN tablets. STEGLATRO is indicated as an adjunct to diet and exerc
Dec. 28 A 12- year-old Duke University spinoff founded by two Duke professors has received regulatory approval for its first drug: once-a-day eye drops for glaucoma patients. Aerie Pharmaceuticals received approval for the medication, Rhopressa, from the Food and Drug Administration on Dec. 18. The company called the FDA approval "a testament to
Tasigna is now the first and only BCR-ABL tyrosine kinase inhibitor to include data about attempting treatment discontinuation in eligible adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase after achieving sustained deep molecular response of MR4.5 (BCR-ABL1 International Scale[ IS].
By a News Reporter-Staff News Editor at Politics& Government Week From Washington, D.C., VerticalNews journalists report that a patent application by the inventors SOHN, Zev; GROSS, Yossi, filed on June 1, 2016, was made available online on December 14, 2017. The patent's assignee is Rainbow Medical Ltd.. The Crystalens.RTM. is an AIOL that has r